Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies
Top Cited Papers
- 1 January 2018
- journal article
- research article
- Published by Elsevier BV
- Vol. 6 (1), 51-64
- https://doi.org/10.1016/S2213-2600(17)30344-2
Abstract
No abstract availableFunding Information
- AstraZeneca
This publication has 28 references indexed in Scilit:
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 2013
- Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjectsJournal of Allergy and Clinical Immunology, 2013
- Blood eosinophil counts rarely reflect airway eosinophilia in children with severe asthmaAllergy, 2013
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- Global asthma prevalence in adults: findings from the cross-sectional world health surveyBMC Public Health, 2012
- MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity functionJournal of Allergy and Clinical Immunology, 2010
- Mepolizumab in refractory eosinophilic asthmaThorax, 2010
- Tissue and BAL Based Biomarkers in AsthmaImmunology and Allergy Clinics of North America, 2007
- Uncontrolled asthma: A review of the prevalence, disease burden and options for treatmentRespiratory Medicine, 2006
- Measurement properties and interpretation of three shortened versions of the asthma control questionnaireRespiratory Medicine, 2005